– UK, London – Smith+Nephew (LON: SN | NYSE: SNN), the global medical technology company, today announced the appointments of Jez Maiden and Simon Lowth to its Board as Independent Non-Executive Directors.
Jez Maiden joins today and will join the Audit Committee and Remuneration Committee, while Simon will join on 1 January 2024 and will serve on the Audit Committee and Nomination & Governance Committee.
About Jeremy Maiden
Jez Maiden has extensive global financial experience across a diverse range of industries and sectors. He retired earlier this year as Group Finance Director at Croda International, the FTSE-100 global specialty chemicals company, and before that held similar roles at National Express Group and Northern Foods. He is currently a Senior Independent Director at Travis Perkins plc and a Non-Executive Director and member of the Audit Committee at Intertek Group plc. Previously, he served as the Senior Independent Director at Synthomer, and at both PZ Cussons and Synthomer he chaired the Audit Committee and served on the Remuneration Committee. He is a fellow of the Chartered Institute of Management Accountants.
About Simon Lowth
Simon Lowth has deep experience in finance, accounting, risk, corporate strategy as well as mergers and acquisitions. He currently serves as Group CFO of BT Group, a role he has held since 2016, and previously performed the same role at BG Group, AstraZeneca, and Scottish Power. Before joining Scottish Power, he led the Industrial Practice of McKinsey in the UK and has a background in engineering. He previously served as a Non-Executive Director on the Board of Standard Chartered. He currently holds no additional external appointments.
Smith+Nephew is a portfolio medical technology business that exists to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 19,000 employees deliver this mission every day, making a difference in patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management, and Sports Medicine & ENT.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generate annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent of the FTSE100
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.